The Collier Report of U.S. Government Contracting

Sampling of Federal Government Funding Actions/Set Asides

In order by amount of set aside monies.

• $149,500 - Friday the 10th of July 2015
  National Aeronautics And Space Administration
  JOHNSON SPACE CENTER
  WITH THE RETIREMENT OF THE SPACE SHUTTLE, BIOLOGICAL SAMPLE RETURN FROM THE INTERNATIONAL SPACE STATION (ISS) WILL BE CHALLENGING DUE TO VOLUME LIMITATIONS ON SOYUZ. BASED ON ADVANCED TECHNOLOGIES DEVELOPED BY NASA AND OTHER ORGANIZATIONS, THIS PROJECT IDENTIFIES HIGH PRIORITY ANALYTES TO BE MEASURED AND VALIDATED AGAINST A LABORATORY GOLD STANDARD (I.E. ELISA, OTHER COMPARABLE ASSAY DETECTION METHODS) IN PHASE III DEVELOPMENT BY AM BIOTECHNOLOGIES THAT WILL SHOW FEASIBILITY FOR POTENTIAL ON-ORBIT DEMONSTRATION ABOARD THE ISS. THE SUCCESSFUL DEPLOYMENT OF LABORATORY ANALYSIS CAPABILITY ON ISS ADDRESSES HUMAN HEALTH COUNTERMEASURES (HHC S) PRIMARY RISK: THE LOSS OF SAMPLE RETURN CAPABILITIES DUE TO THE RETIREMENT OF THE SPACE SHUTTLE. RATHER THAN RELYING ON GROUND-BASED ANALYSIS, ON-ORBIT ANALYSIS PROVIDES `POINT OF CARE ASSESSMENT OF ANALYTES OF INTEREST TO THE BIOMEDICAL RESEARCH COMMUNITY AT NASA. IT MAY ALSO BE OF VALUE FOR EXPLORATION MEDICAL CAPABILITIES INTEGRATED RESEARCH PLAN GAP EXMC 4.15: LACK OF MINIMALLY INVASIVE INFLIGHT LABORATORY CAPABILITIES WITH LIMITED CONSUMABLES REQUIRED FOR DIAGNOSING IDENTIFIED EXPLORATION MEDICAL CONDITIONS. NASA HHC WILL PROVIDE FUNDING FOR PHASE III DEVELOPMENT OF A THIOAPTAMER FEASIBILITY ASSAY DERIVED FROM A SELECT PANEL OF ANALYTES. THE SELECT ASSAY WILL BE DEVELOPED AND IMPLEMENTED ON A MICROFLUIDIC GEL ELECTROPHORESIS INSTRUMENT DEVELOPED BY SANDIA NATIONAL LABORATORIES. THE GOAL OF THIS CONTRACT IS TO PROVIDE DEVELOPMENT AND PERFORMANCE TESTING SERVICES FOR AN ASSAY TO ONE PROTEIN TARGET. TNF- (TUMOR NECROSIS FACTOR ALPHA) IS THE PRIMARY PROTEIN TARGET; HOWEVER, THIOAPTAMER SELECTIONS TO TWO OTHER PROTEIN TARGETS (TBD AND TBD) MAY ALSO BE ATTEMPTED TO MITIGATE THE RISK THAT A THIOAPTAMER WITH SUFFICIENT BINDING AFFINITY AND SPECIFICITY FOR USE IN AN ASSAY FOR TNF- IS NOT DISCOVERED. THE PERFORMER IS EXPECTED TO PROVIDE MONTHLY REPORTS TO MONITOR PROGRESS AND ASSAY DEVELOPMENT.

  ---

• $149,500 - Thursday the 5th of September 2013
  National Aeronautics And Space Administration
  NASA SHARED SERVICES CENTER
  AM BIOTECHNOLOGIES (AM) IN PARTNERSHIP WITH SANDIA NATIONAL LABORATORIES WILL DEVELOP A THIOAPTAMER DIAGNOSTIC SYSTEM (TDS) IN RESPONSE TO TOPIC X10.01 REUSABLE DIAGNOSTIC LAB TECHNOLOGY. THE TDS WILL QUICKLY QUANTIFY CLINICALLY RELEVANT BIOMARKERS IN FLIGHT USING ONLY MICROLITERS OF VIRTUALLY ANY COMPLEX SAMPLE. THE SYSTEM COMBINES AMBIENT-STABLE, LONG-SHELF-LIFE AFFINITY AGENT ASSAYS WITH A HANDHELD MICROFLUIDIC GEL ELECTROPHORESIS AFFINITY ASSAY QUANTIFICATION TECHNOLOGY. THE SYSTEM IS EASY TO USE, COMPATIBLE WITH OPERATION IN MICROGRAVITY, AND DESIGNED TO PERMIT SIMULTANEOUS QUANTIFICATION OF 32 OR MORE BIOMARKERS FROM A SINGLE ASTRONAUT SAMPLE.

  ---